drugset
drugset / Trial / NCT05452005

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

NCT05452005 ↗

Phase 1 Recruiting 20 enrolled University of California, Davis United States Department of Defense · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.

Timeline

Start
2022-09-13
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-αvβ6-BP Diagnostic / imaging agent 370 mbq Intravenous

Indications

metastatic malignant neoplasm in the brain non-small cell lung carcinoma